Literature DB >> 10958351

Definition of peptide binding motifs amongst the HLA-A*30 allelic group.

P Krausa1, C Münz, W Keilholz, S Stevanovic, E Y Jones, M Browning, M Bunce, H G Rammensee, A McMichael.   

Abstract

HLA class I molecules present endogenously processed peptide ligands for surveillance by the T-cell receptor. This potentially immunogenic surface of HLA and peptide is a consequence of the polymorphism found within the HLA molecule and its preference for ligand binding together with peptide conformation within the binding groove. To investigate the relation between the polymorphic differences between some closely related HLA alleles and their effect on peptide preference, transfectants were established, each containing one of four allelic variants of HLA-A*30. Peptides from all four transfectants were eluted, and both individual ligands and peptide pools were sequenced. The data shows two distinct peptide motifs which distinguish A*3001 from the other three known A*30 variants. Differences in preferences at minor positions within the peptide sequence were noted between A*3002, A*3003 and A*3004, providing additional evidence of the implications of sequence polymorphism to HLA function.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10958351     DOI: 10.1034/j.1399-0039.2000.560102.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  11 in total

1.  Classification of A1- and A24-supertype molecules by analysis of their MHC-peptide binding repertoires.

Authors:  John Sidney; Scott Southwood; Alessandro Sette
Journal:  Immunogenetics       Date:  2005-07-08       Impact factor: 2.846

2.  The peptide-binding specificity of HLA-A*3001 demonstrates membership of the HLA-A3 supertype.

Authors:  Kasper Lamberth; Gustav Røder; Mikkel Harndahl; Morten Nielsen; Claus Lundegaard; Claus Schafer-Nielsen; Ole Lund; Soren Buus
Journal:  Immunogenetics       Date:  2008-09-04       Impact factor: 2.846

3.  Rapid definition of five novel HLA-A*3002-restricted human immunodeficiency virus-specific cytotoxic T-lymphocyte epitopes by elispot and intracellular cytokine staining assays.

Authors:  P J Goulder; M M Addo; M A Altfeld; E S Rosenberg; Y Tang; U Govender; N Mngqundaniso; K Annamalai; T U Vogel; M Hammond; M Bunce; H M Coovadia; B D Walker
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

4.  Human leukocyte antigens A*3001 and A*3002 show distinct peptide-binding patterns of the Mycobacterium tuberculosis protein TB10.4: consequences for immune recognition.

Authors:  Rebecca Axelsson-Robertson; Raija K Ahmed; Frank F Weichold; Marthie M Ehlers; Marleen M Kock; Donata Sizemore; Jerry Sadoff; Markus Maeurer
Journal:  Clin Vaccine Immunol       Date:  2010-11-17

5.  Identification of human immunodeficiency virus type 1 subtype C Gag-, Tat-, Rev-, and Nef-specific elispot-based cytotoxic T-lymphocyte responses for AIDS vaccine design.

Authors:  V Novitsky; N Rybak; M F McLane; P Gilbert; P Chigwedere; I Klein; S Gaolekwe; S Y Chang; T Peter; I Thior; T Ndung'u; F Vannberg; B T Foley; R Marlink; T H Lee; M Essex
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

6.  T cell epitope clustering in the highly immunogenic BZLF1 antigen of Epstein-Barr virus.

Authors:  Melissa J Rist; Michelle A Neller; Jacqueline M Burrows; Scott R Burrows
Journal:  J Virol       Date:  2014-10-29       Impact factor: 5.103

7.  A single amino-acid polymorphism in pocket A of HLA-A*6602 alters the auxiliary anchors compared with HLA-A*6601 ligands.

Authors:  Christina Bade-Doeding; Holger-Andreas Elsner; Britta Eiz-Vesper; Axel Seltsam; Ute Holtkamp; Rainer Blasczyk
Journal:  Immunogenetics       Date:  2004-04-30       Impact factor: 2.846

8.  MHC class I loaded ligands from breast cancer cell lines: A potential HLA-I-typed antigen collection.

Authors:  Dmitri V Rozanov; Nikita D Rozanov; Kami E Chiotti; Ashok Reddy; Phillip A Wilmarth; Larry L David; Seung W Cha; Sunghee Woo; Pavel Pevzner; Vineet Bafna; Gregory G Burrows; Juha K Rantala; Trevor Levin; Pavana Anur; Katie Johnson-Camacho; Shaadi Tabatabaei; Daniel J Munson; Tullia C Bruno; Jill E Slansky; John W Kappler; Naoto Hirano; Sebastian Boegel; Bernard A Fox; Colt Egelston; Diana L Simons; Grecia Jimenez; Peter P Lee; Joe W Gray; Paul T Spellman
Journal:  J Proteomics       Date:  2018-01-10       Impact factor: 4.044

9.  Association of HLA alleles with Plasmodium falciparum severity in Malian children.

Authors:  K E Lyke; M A Fernández-Viňa; K Cao; J Hollenbach; D Coulibaly; A K Kone; A Guindo; L A Burdett; R J Hartzman; A R Wahl; W H Hildebrand; O K Doumbo; C V Plowe; M B Sztein
Journal:  Tissue Antigens       Date:  2011-03-30

10.  Soluble HLA technology as a strategy to evaluate the impact of HLA mismatches.

Authors:  Heike Kunze-Schumacher; Rainer Blasczyk; Christina Bade-Doeding
Journal:  J Immunol Res       Date:  2014-09-01       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.